Let’s take a look at the 2025 cannabis coverage on medical cannabis research and medicine to catch up on industry trends and innovations.
|Articles|June 8, 2022
Cannabis Science and Technology
- Psychedelics: New Frontiers in Alternative Medicine
- Volume 5
- Issue s1
May/June 2022 Digital Edition
View our interactive May/June 2022 digital edition.
Advertisement
Click here to view our interactive May/June supplement
Articles include:
- The Path to Legalized, Accessible Psilocybin Therapy
- A New Clinical Trial in South Africa Aims to Study the Effect of Psilocybin on HIV Positive Women with Major Depressive Disorder
- Anticipating Legalization: Making Psilocybin Accessible
- A Highly Contiguous Draft Reference Genome for the Psilocybe Cubensis Mushroom Is Now Available
- Psilocybin Therapy for PTSD and Depression
- Cannabis and Psychedelics Research: A Conversation with Dr. Denise Vidot
Articles in this issue
over 4 years ago
The Path to Legalized, Accessible Psilocybin Therapyover 4 years ago
Anticipating Legalization: Making Psilocybin Accessibleover 4 years ago
Psilocybin Therapy for PTSD and DepressionAdvertisement
Related to this article
Let’s take a look at the 2025 cannabis coverage on cannabis research to catch up on industry trends and innovations.
It’s that time of year again—the Cannabis Science and Technology (CST) top 10 articles from the previous year. CST published a wide variety of content throughout 2025. Here is just a small snippet of some of the top articles that our readers enjoyed. See if any of your favorites made the list!
Our top cannabis news topics this week: President Trump’s executive order on cannabis rescheduling, hemp regulation legislation, NY program using cannabis to reduce opioid use, cannabis genetics and cannabinoid profiles, and the latest cannabis research studies.
This month’s webinar explored published research studies on cannabis and its effect on opioids, substance use reduction, alcohol use, and autism symptoms.
President Trump signed an executive order directing federal agencies to reclassify cannabis from Schedule I to Schedule III controlled substances.
Zacariah Hildenbrand, PhD and Adam Jacques discuss how cannabis genetics affect cannabinoids.
A recent study found that medical cannabis may play a role in decreasing opioid use.
Advertisement
Advertisement